Hubei Cancer Hospital — Wuhan, Hubei

Public research footprint of Hubei Cancer Hospital, compiled from the ClinicalTrials.gov public registry.

366

Registered studies

223

Active

127

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Non-small Cell Lung Cancer (NSCLC) · Esophageal Squamous Cell Carcinoma (ESCC) · Colorectal Neoplasms · HER2-positive Breast Cancer

Recently updated registry entries

NCT07554339 — A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell… (Recruiting)
NCT06997497 — A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… (Recruiting)
NCT06459180 — A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Hubei Cancer Hospital?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.